fixed-duration therapy with venetoclax-obinutuzumab in frontline cll
Published 5 years ago • 1.7K plays • Length 10:24Download video MP4
Download video MP3
Similar videos
-
1:32
cll14: feasibility of fixed-duration frontline therapy in cll
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
7:55
clinical trials of fixed duration treatments & novel targets in cll
-
1:56
the future of fixed-duration therapy in cll
-
2:41
fixed-duration vs continuous therapy in cll
-
2:08
the role of venetoclax in the treatment of cll
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
4:05
comparing continuous and fixed duration therapy in cll
-
2:51
the optimum approach to frontline treatment of cll in 2021
-
0:48
venetoclax and obinutuzumab for cll
-
1:13
factors to consider when selecting between continuous and fixed-duration therapy in cll
-
2:08
choosing between continuous versus fixed-duration therapy in cll
-
12:46
fixed duration treatment strategies in cll
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
2:03
venetoclax and obinutuzumab combination therapy for cll
-
1:34
time-limited vs continuous therapy in cll treatment
-
1:28
the future of cll treatment
-
3:22
combining venetoclax and obinutuzumab in the treatment of cll